Chiesi Pharmaceuticals
VC Fund
Parma, Italy
Chiesi Pharmaceuticals is a VC fund in Parma focused on Medical and Health Care. Chiesi Pharmaceuticals provides research, development, production, and marketing of medicines for respiratory, neonatology, rare diseases. It was established in 1935 and is based in Parma, Emilia-Romagna.
- Total investments:
- 2
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Chiesi Pharmaceuticals invests in
Stages Chiesi Pharmaceuticals invests in
Countries Chiesi Pharmaceuticals invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Alberto Chiesi
|
|||
|
Danilo Piroli
|
|||
Diego Ardigò
|
|||
|
Paolo Chiesi
|
|||
Raffaella Monno
|
|||
| See all 8 contacts → | |||
Investment Focus
Industry
- Medical 2 (100%)
- Health Care 2 (100%)
- Biotechnology 2 (100%)
- Genetics 1 (50%)
- Pharmaceutical 1 (50%)
Stage
- Series B 1 (50%)
- Private Equity 1 (50%)
Country
- Canada 1 (50%)
- The Netherlands 1 (50%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Alberto Chiesi
Chairman
|
Chairman | Total investments: 0 | Find email | |
|
Danilo Piroli
Director
|
Director | Total investments: 0 | Find email | |
|
Diego Ardigò
Global Rare Diseases, Research & Development Head
|
Global Rare Diseases, Research & Development Head | Total investments: 0 | Find email | |
|
Paolo Chiesi
Vice Chairman
|
Vice Chairman | Total investments: 0 | Find email | |
|
Raffaella Monno
Head of Real World Evidence, R&D Global Clinical Development
|
Head of Real World Evidence, R&D Global Clinical Development | Total investments: 0 | Find email | |
| See all 8 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cyclica
|
Cyclica is the partner of choice for data-driven drug discovery. The software developed by the company uses biophysics and artificial intelligence (AI) to improve drug discovery practices by generating a list of putative ligand-protein interactions, allowing health institutions to prioritize lead candidates, elucidate adverse effects, andunderstand repurposing opportunities. | $16.9M / Series B / Jun 24, 2020 | |
UniQure
|
uniQure is a leader in the field of gene therapy and had developed the first and currently the only gene therapy product to receive regulatory approval in the European Union. Gene therapy offers the prospect of long-term and potentially curative benefit to patients with genetic or acquired diseases by directing the expression of a therapeuticprotein or restoring the expression of a missing protein through a single administration.Our first product, Glybera, was approved by the European Commission in October 2012 under exceptional circumstances for the treatment of a subset of patients with lipoprotein lipase deficiency, or LPLD, a potentially life-threatening, orphan metabolic disease.We are also developing a pipeline of additional adeno-associated virus (AAV)-based gene therapies through multiple collaborations. We develop our gene therapies using our innovative, modular technology platform, including our proprietary manufacturing process. We initially are focused on orphan diseases but believe that we will also be able to develop gene therapies targeting chronic and degenerative diseases that affect larger populations. | $58M / Private Equity / Jul 09, 2013 |
Co-Investors
Coller Capital
1 deal together
Drive Capital
1 deal together
Forbion Capital Partners
1 deal together
GreenSky Ventures
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Chiesi Pharmaceuticals invest in?
Chiesi Pharmaceuticals invests primarily in Medical, Health Care and Biotechnology startups, most often at Series B and Private Equity stage. Most of the 2 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Chiesi Pharmaceuticals?
Public channels for Chiesi Pharmaceuticals include LinkedIn, the website linked on this profile and Facebook. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Chiesi Pharmaceuticals?
The team at Chiesi Pharmaceuticals includes Alberto Chiesi (Chairman), Danilo Piroli (Director) and Diego Ardigò (Global Rare Diseases, Research & Development Head), among 8 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
